

Christine Lebrun-frenay

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4173563/christine-lebrun-frenay-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

163
papers

6,702
citations

43
h-index

78
g-index

231
ext. papers

7,974
ext. citations

5.1
avg, IF

5.33
L-index

#	Paper	IF	Citations
163	Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study.. <i>Neurology and Therapy</i> , 2022 , 1	4.6	0
162	CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory DiseasesS Treatments. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	2
161	Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal.. <i>Neurotherapeutics</i> , 2022 , 1	6.4	0
160	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211069068	5	1
159	Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study.. <i>Journal of Neuroinflammation</i> , 2022 , 19, 62	10.1	4
158	Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities.. <i>Frontiers in Immunology</i> , 2022 , 13, 864133	8.4	1
157	Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1458-1463	5	3
156	Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 232-238	5.3	3
155	Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome. <i>JAMA Network Open</i> , 2021 , 4, e2128271	10.4	3
154	BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1556-1563	5	2
153	Untreated patients with multiple sclerosis: A study of French expert centers. <i>European Journal of Neurology</i> , 2021 , 28, 2026-2036	6	3
152	Hemophagocytic Lymphohistiocytosis Gene Mutations in Adult Patients Presenting With CLIPPERS-Like Syndrome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	3
151	Vaccinations in multiple sclerosis patients receiving disease-modifying drugs. <i>Current Opinion in Neurology</i> , 2021 , 34, 322-328	7.1	13
150	Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis. <i>Neurotherapeutics</i> , 2021 , 18, 938-948	6.4	2
149	MRI findings in blinded trials should be available to treating physicians - Yes. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 812-813	5	1
148	Comparison of Simoa and Ella to assess serum neurofilament-light chain in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 1141-1150	5.3	17
147	Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	2

146	Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 2280-2283	5	0
145	Cerebrospinal Fluid IL-17A Could Predict Acute Disease Severity in Non-NMDA-Receptor Autoimmune Encephalitis. <i>Frontiers in Immunology</i> , 2021 , 12, 673021	8.4	3
144	Pregnancy with multiple sclerosis. <i>Revue Neurologique</i> , 2021 , 177, 180-194	3	8
143	Digital biomarkers can highlight subtle clinical differences in radiologically isolated syndrome compared to healthy controls. <i>Journal of Neurology</i> , 2021 , 268, 1316-1322	5.5	0
142	Alexithymia in multiple sclerosis: Clinical and radiological correlations. <i>Revue Neurologique</i> , 2021 , 177, 302-311	3	2
141	Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis. <i>Neurotherapeutics</i> , 2021 , 18, 378-386	6.4	0
140	Cerebellar volume loss in radiologically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 130-133	5	8
139	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1838-1851	5	2
138	The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 53, 103012	4	3
137	How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP). <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 53, 103076	4	3
136	The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - No. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1824-1826	5	3
135	Association of Immunosuppression and Viral Load With Subcortical Brain Volume in an International Sample of People Living With HIV. <i>JAMA Network Open</i> , 2021 , 4, e2031190	10.4	4
134	Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event. <i>Annals of Neurology</i> , 2020 , 88, 407-417	9.4	35
133	Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. <i>JAMA Neurology</i> , 2020 , 77, 1079-1088	17.2	235
132	Video-oculography in multiple sclerosis: Links between oculomotor disorders and brain magnetic resonance imaging (MRI). <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 40, 101969	4	2
131	Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies. <i>Journal of Neuroinflammation</i> , 2020 , 17, 128	10.1	5
130	Validation of a rapid and easy-to-perform screening test for neurocognitive impairment in HIV+ patients. <i>Journal of the Neurological Sciences</i> , 2020 , 410, 116664	3.2	3
129	Effects on Melanoma Cell Lines Suggest No Significant Risk of Melanoma Under Cladribine Treatment. <i>Neurology and Therapy</i> , 2020 , 9, 599-604	4.6	2

128	Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France. <i>JAMA Neurology</i> , 2020 , 77, 94-102	17.2	18
127	Prospective validation of the PML risk biomarker I-selectin and influence of natalizumab extended intervals. <i>Neurology</i> , 2019 , 93, 550-554	6.5	11
126	Impact of executive dysfunction on naming ability in multiple sclerosis. <i>Revue Neurologique</i> , 2019 , 175, 552-559	3	1
125	CLIPPERS and its mimics: evaluation of new criteria for the diagnosis of CLIPPERS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 1027-1038	5.5	32
124	Immunoglobulin G4-related hypertrophic pachymeningitis: A case-oriented review. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6, e568	9.1	17
123	Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. <i>Revue Neurologique</i> , 2019 , 175, 341-357	3	9
122	Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 31, 173-188	4	26
121	Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217319836664	2	15
120	Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France. <i>Journal of Neurology</i> , 2019 , 266, 888-901	5.5	6
119	Imaging spectrum of Bing-Neel syndrome: how can a radiologist recognise this rare neurological complication of Waldenström's macroglobulinemia?. <i>European Radiology</i> , 2019 , 29, 102-114	8	12
118	Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. <i>Neurology</i> , 2019 , 93, e635-e646	6.5	24
117	Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 28, 109-116	4	4
116	International consensus on quality standards for brain health-focused care in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1809-1818	5	31
115	De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 618-621	5	2
114	Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 669-677	5	14
113	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 591-600	5	9
112	Cervical spinal cord atrophy: An early marker of progressive MS onset. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018 , 5, e435	9.1	43
111	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. <i>Neurology</i> , 2018 , 90, e1858-e1869	6.5	268

110	Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients. <i>Journal of Neurology</i> , 2018 , 265, 2251-2259	5.5	16
109	Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs. <i>CNS Drugs</i> , 2018 , 32, 939-949	6.7	44
108	Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders. <i>Neurology and Therapy</i> , 2018 , 7, 373-383	4.6	19
107	Anomalies Characteristic of Central Nervous System Demyelination: Radiologically Isolated Syndrome. <i>Neurologic Clinics</i> , 2018 , 36, 59-68	4.5	10
106	Digestive side-effects with teriflunomide: Thoughts on lactose. <i>Revue Neurologique</i> , 2018 , 174, 722-725	3	3
105	Gender Inequities in the Multiple Sclerosis Community: A Call for Action. <i>Annals of Neurology</i> , 2018 , 84, 958-959	9.4	5
104	Bevacizumab: Is the lower the better for glioblastoma patients in progression?. <i>Bulletin Du Cancer</i> , 2018 , 105, 1135-1146	2.4	2
103	MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study. <i>CNS Drugs</i> , 2018 , 32, 661-672	6.7	22
102	Should we treat patients with radiologically isolated syndrome (RIS)? Comments. <i>Revue Neurologique</i> , 2018 , 174, 696-698	3	2
101	Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies. <i>Neurology</i> , 2017 , 88, 514-524	6.5	40
100	Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study. <i>Journal of the Neurological Sciences</i> , 2017 , 373, 335-338	3.2	49
99	HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Disorders (HAND). <i>Heliyon</i> , 2017 , 3, e00245	3.6	11
98	Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. <i>Journal of Autoimmunity</i> , 2017 , 79, 84-90	15.5	51
97	Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e346	9.1	9
96	Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. <i>European Journal of Endocrinology</i> , 2017 , 176, 769-777	6.5	79
95	Multiple immune disorders after natalizumab discontinuation: After the CIRIS, the SIRIS?. <i>Revue Neurologique</i> , 2017 , 173, 222-224	3	7
94	Cognition and quality of life in clinically isolated syndrome patients starting a disease modifying therapy in the QUALICIS study may not predict treatment response at one year. <i>Journal of the Neurological Sciences</i> , 2017 , 382, 73-78	3.2	3
93	Radiologically isolated syndrome in children: Clinical and radiologic outcomes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e395	9.1	24

92	Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. <i>PLoS ONE</i> , 2017 , 12, e0168834	3.7	15
91	Decreased prevalence of cancer in patients with multiple sclerosis: A case-control study. <i>PLoS ONE</i> , 2017 , 12, e0188120	3.7	16
90	A Case Report of Solitary Sclerosis: This is Really Multiple Sclerosis. <i>Neurology and Therapy</i> , 2017 , 6, 259-263	4.6	9
89	Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 18, 161-163	4	2
88	Radiologically isolated syndrome should be treated with disease-modifying therapy - Commentary. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1821-1823	5	2
87	Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , 2017 , 82, 186-195	9.4	13
86	New insights into the burden and costs of multiple sclerosis in Europe: Results for France. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 65-77	5	17
85	A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication. <i>Journal of NeuroVirology</i> , 2017 , 23, 216-225	3.9	14
84	Signes et symptômes de la sclérose en plaques 2017 , 3-78		
83	Diagnostic positif de la sclérose en plaques 2017 , 79-111		
82	Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis. <i>Journal of Neuroimmunology</i> , 2016 , 298, 79-81	3.5	31
81	CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. <i>Neurology</i> , 2016 , 87, 2491-2494	6.5	17
80	Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome. <i>Annals of Neurology</i> , 2016 , 79, 288-94	9.4	96
79	Evaluation of quality of life and fatigue in radiologically isolated syndrome. <i>Revue Neurologique</i> , 2016 , 172, 392-5	3	15
78	Should a psychotic or manic episode be considered an early manifestation of Multiple Sclerosis? A multiple case study. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 6, 93-96	4	8
77	Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study. <i>Neurology</i> , 2016 , 86, 771-8	6.5	57
76	Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. <i>Neurology</i> , 2016 , 86, 920-30	6.5	80
75	Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study. <i>Journal of the Neurological Sciences</i> , 2016 , 363, 69-76	3.2	32

74	False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1231-4	5	9
73	MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1719-1731	5	201
72	Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders. <i>Journal of the Neurological Sciences</i> , 2016 , 368, 334-6	3.2	7
71	Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. <i>Journal of Neurology</i> , 2015 , 262, 2329-35	5.5	71
70	Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. <i>Lancet, The</i> , 2015 , 386, 974-81	40	105
69	Tear analysis as a tool to detect oligoclonal bands in radiologically isolated syndrome. <i>Revue Neurologique</i> , 2015 , 171, 390-3	3	17
68	The radiologically isolated syndrome. <i>Revue Neurologique</i> , 2015 , 171, 698-706	3	15
67	Solitary sclerosis: Experience from three French tertiary care centres. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1216	5	9
66	Country break-out session highlights. <i>Neurodegenerative Disease Management</i> , 2015 , 5, 31-7	2.8	
65	High doses of biotin in chronic progressive multiple sclerosis: a pilot study. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 159-69	4	153
64	Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients. <i>Brain</i> , 2015 , 138, 284-92	11.2	41
63	Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. <i>PLoS ONE</i> , 2015 , 10, e0132033	3.7	40
62	Demonstration of a lexical access deficit in relapsing-remitting and secondary progressive forms of multiple sclerosis. <i>Revue Neurologique</i> , 2014 , 170, 527-30	3	5
61	Uncommon foreign body reaction caused by derivation drain mimicking high grade CNS tumor. <i>Journal of the Neurological Sciences</i> , 2014 , 340, 237-8	3.2	
60	Radiologically isolated syndrome: 5-year risk for an initial clinical event. <i>PLoS ONE</i> , 2014 , 9, e90509	3.7	190
59	Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?. <i>Aids</i> , 2014 , 28, 493-501	3.5	43
58	A prospective study of patients with brain MRI showing incidental t2 hyperintensities addressed as multiple sclerosis: a lot of work to do before treating. <i>Neurology and Therapy</i> , 2014 , 3, 123-32	4.6	17
57	The HV3 Score: A New Simple Tool to Suspect Cognitive Impairment in Multiple Sclerosis in Clinical Practice. <i>Neurology and Therapy</i> , 2014 , 3, 113-22	4.6	4

56	Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. <i>JAMA Neurology</i> , 2014 , 71, 436-41	17.2	110
55	Moving to fingolimod from natalizumab in multiple sclerosis-reply. <i>JAMA Neurology</i> , 2014 , 71, 925	17.2	1
54	Risk for nevus transformation and melanoma proliferation and invasion during natalizumab treatment: four years of dermoscopic follow-up with immunohistological studies and proliferation and invasion assays. <i>JAMA Dermatology</i> , 2014 , 150, 901-3	5.1	9
53	Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1135-9	5	13
52	Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study. <i>Journal of NeuroVirology</i> , 2013 , 19, 376-82	3.9	22
51	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. <i>Nature Genetics</i> , 2013 , 45, 1353-60	36.3	934
50	L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. <i>Neurology</i> , 2013 , 81, 865-71	6.5	127
49	Longitudinal follow-up of vision in a neuromyelitis optica cohort. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1320-2	5	23
48	Les traitements de première ligne dans la sclérose en plaques. <i>Pratique Neurologique - FMC</i> , 2012 , 3, 73-89	0	
47	Increased risk of multiple sclerosis relapse after in vitro fertilisation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 796-802	5.5	77
46	Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. <i>Muscle and Nerve</i> , 2012 , 46, 687-91	3.4	53
45	Treat patients with radiologically isolated syndrome when the MRI brain scan shows dissemination in time: yes. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1531-2	5	9
44	Impact of pregnancy on conversion to clinically isolated syndrome in a radiologically isolated syndrome cohort. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1297-302	5	48
43	Endermology: a treatment for injection-induced lipoatrophy in multiple sclerosis patients treated with sub cutaneous glatiramer acetate. <i>Clinical Neurology and Neurosurgery</i> , 2011 , 113, 721-4	2	7
42	Carnitine serum levels and levocarnitine administration in multiple sclerosis patients treated with natalizumab. <i>European Journal of Neurology</i> , 2011 , 18, e63-4	6	1
41	EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis. <i>Journal of Neuro-Oncology</i> , 2011 , 102, 171-8	4.8	20
40	Cancer and multiple sclerosis in the era of disease-modifying treatments. <i>Journal of Neurology</i> , 2011 , 258, 1304-11	5.5	43
39	Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. <i>Brain</i> , 2011 , 134, 693-703	11.2	76

38	A benign form of neuromyelitis optica: does it exist?. <i>Archives of Neurology</i> , 2011 , 68, 918-24		44
37	Evolution of nevi during treatment with natalizumab: A prospective follow-up of patients treated with natalizumab for multiple sclerosis. <i>Archives of Dermatology</i> , 2011 , 147, 72-6		16
36	Cutaneous Side-effects of Immunomodulators in MS. <i>International MS Journal</i> , 2011 , 17, 88-94		12
35	Cognitive function in radiologically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 919-25	5	90
34	Giant urticaria and persistent neutralizing antibodies after the first natalizumab infusion. <i>Neurology</i> , 2010 , 74, 1394-5	6.5	8
33	Les syndromes radiologiquement isolés. <i>Pratique Neurologique - FMC</i> , 2010 , 1, F25-F28	0	
32	Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 87-92	5	33
31	Les syndromes radiologiquement isolés. <i>Neurologie Com</i> , 2010 , 2, 139-141		
30	Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. <i>Archives of Neurology</i> , 2009 , 66, 841-6		145
29	Recurrent pericarditis due to natalizumab treatment. <i>Neurology</i> , 2009 , 72, 1616-7	6.5	3
28	Successful treatment of refractory generalized myasthenia gravis with rituximab. <i>European Journal of Neurology</i> , 2009 , 16, 246-50	6	86
27	Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 399-405	5	80
26	Impact of disease-modifying treatments in North African migrants with multiple sclerosis in France. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 933-9	5	3
25	Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008 , 79, 195-8	5.5	92
24	Cognitive functions in neuromyelitis optica. <i>Archives of Neurology</i> , 2008 , 65, 84-8		86
23	Natural history of multiple sclerosis with childhood onset. <i>New England Journal of Medicine</i> , 2007 , 356, 2603-13	59.2	415
22	Turcot syndrome confirmed with molecular analysis. <i>European Journal of Neurology</i> , 2007 , 14, 470-2	6	12
21	Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. <i>European Journal of Neurology</i> , 2007 , 14, 391-8	6	53

20	A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate. <i>European Journal of Neurology</i> , 2007 , 14, 1266-74	6	12
19	Acute fulminant demyelinating disease: a descriptive study of 60 patients. <i>Archives of Neurology</i> , 2007 , 64, 1426-32		117
18	Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 256-9	5	161
17	More severe disability of North Africans vs Europeans with multiple sclerosis in France. <i>Neurology</i> , 2007 , 68, 29-32	6.5	50
16	Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 321-4	5	35
15	Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. <i>Neurology</i> , 2005 , 65, 1950-3	6.5	122
14	First-line nitrosourea-based chemotherapy in symptomatic non-resectable supratentorial pure low-grade astrocytomas. <i>European Journal of Neurology</i> , 2005 , 12, 685-90	6	43
13	Acute aphasia in multiple sclerosis: A multicenter study of 22 patients. <i>Neurology</i> , 2004 , 62, 974-7	6.5	45
12	Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. <i>Journal of the Neurological Sciences</i> , 2004 , 218, 73-7	3.2	51
11	Long-term outcome of oligodendrogliomas. <i>Neurology</i> , 2004 , 62, 1783-7	6.5	71
10	Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 521-5	5	103
9	Interferon-beta treatment in patients with childhood-onset multiple sclerosis. <i>Journal of Pediatrics</i> , 2001 , 139, 443-6	3.6	102
8	Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. <i>Annals of Oncology</i> , 2001 , 12, 217-9	10.3	84
7	Up-front chemotherapy with fotemustine (F) / cisplatin (CDDP) / etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas. <i>European Journal of Cancer</i> , 2000 , 36, 1026-31	7.5	32
6	Leukoencephalopathy in multiple myeloma: two case reports. <i>Annals of Oncology</i> , 1999 , 10, 1515-7	10.3	7
5	Nonconvulsive status epilepticus of frontal origin. <i>Neurology</i> , 1999 , 52, 1174-83	6.5	85
4	Solitary meningeal plasmacytomas. <i>Annals of Oncology</i> , 1997 , 8, 791-5	10.3	9
3	Recurrent bowel occlusion with oral ondansetron with no side effects of the intravenous route: a previously unknown adverse event. <i>Annals of Oncology</i> , 1997 , 8, 919-20	10.3	5

2 Progressive spastic paraparesis revealing primary hyperparathyroidism. *Neurology*, **1994**, 44, 178-9 6.5 12

1 Smaller limbic structures are associated with greater immunosuppression in over 1000 HIV-infected adults across five continents: Findings from the ENIGMA-HIV Working Group 1